Monday, May 17, 2021 6:15:37 PM
Other Events
On May 7, 2021, the Company entered into a strategic collaboration and development agreement (the "Agreement") with Nebula Genomics ("Nebula"). Under the terms of the agreement, the Company may offer Nebula products to its customers, including 30x whole genome sequencing testing, analytical tools, and other products, which are fulfilled by Nebula. The Company will have a revenue sharing agreement with Nebula for each product ordered by its customers.
Nebula will provide the Company with technologies and services to assist it in direct to consumer and clinical diagnostic markets in the areas of privacy technologies, such as block chain, and analytical tools. Nebula will provide access to its 30x whole genome sequencing capabilities. In addition, the Company and Nebula intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. These development activities will be governed by joint scientific advisory boards with representation from both companies.
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM